This case study on Monoclonal Antibody (mAb) development highlights how modern bioprocessing balances speed-to-market with high-quality yields. The Challenge
The is a landmark document in the biopharmaceutical industry, serving as a comprehensive template for applying Quality by Design (QbD) principles to the development of monoclonal antibodies (mAbs) . Published in 2009 by the CMC Biotech Working Group , it simulates the development of a hypothetical IgG1 monoclonal antibody to demonstrate how systematic, risk-based approaches can enhance process understanding and ensure product quality. Core Framework of the A-Mab Study A Mab A Case Study In Bioprocess Development
A Mab reached the clinic in 28 months from transfection – 6 months ahead of schedule. Today, it’s a blockbuster therapy. But the bioprocess continues to evolve. The team is now implementing (perfused N-1 and connected capture) to boost productivity to 15 g/L and reduce COGS by 40%. This case study on Monoclonal Antibody (mAb) development
Starts with choosing a host cell (often CHO cells ) and optimizing the genetic expression of the antibody. Core Framework of the A-Mab Study A Mab
These seemingly simple numbers dictate the entire manufacturing strategy. A Mab for subcutaneous injection requires high concentration (≥100 mg/mL) and extremely low viscosity, which immediately rules out certain purification methods and formulation buffers.